ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,561Medicare Part D Prescriptions Filled, Including Refills

Rank: 124 out of 761

$432K Total Retail Price of All Prescriptions

Rank: 178 out of 761

496 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
45% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 496 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

11% of this provider’s 496 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 7,986 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LISINOPRIL 532 448 1 1
SIMVASTATIN 456 412 2 2
HYDROCHLOROTHIAZIDE 374 340 3 11
AMLODIPINE BESYLATE 358 299 4 6
PRAVASTATIN SODIUM 352 299 5 20
LEVOTHYROXINE SODIUM 322 265 6 3
OMEPRAZOLE 273 236 7 4
CITALOPRAM HBR 249 234 8 19
METOPROLOL SUCCINATE 226 183 9 16
ATORVASTATIN CALCIUM 214 187 10 12
METFORMIN HCL 211 170 11 10
WARFARIN SODIUM 189 161 12 9
ALENDRONATE SODIUM 182 166 13 21
HYDROCODONE-ACETAMINOPHEN 171 117 S3 14 5
METOPROLOL TARTRATE 163 137 15 14
LOSARTAN POTASSIUM 145 129 16 13
ATENOLOL 129 127 17 8
FUROSEMIDE 123 115 18 7
GLIPIZIDE ER 122 112 19 124
LOVASTATIN 120 119 20 17
ADVAIR DISKUS 119 107 21 37
ZOLPIDEM TARTRATE 103 81 22 22
GABAPENTIN 99 73 23 15
POTASSIUM CHLORIDE 89 89 24 18
GLIPIZIDE XL 84 60 25 148
GLIPIZIDE 82 69 26 39
TRAZODONE HCL 79 46 27 23
DONEPEZIL HCL 78 78 28 33
NAMENDA 75 75 29 59
ROPINIROLE HCL 70 56 30 95
CLONIDINE HCL 68 45 31 69
RANITIDINE HCL 68 38 31 52
SPIRIVA 66 54 33 56
LISINOPRIL-HYDROCHLOROTHIAZIDE 63 57 34 35
ALLOPURINOL 60 58 35 28
LIPITOR 58 45 36 147
GLIMEPIRIDE 58 36 36 48
LANTUS 58 44 36 41
OXYBUTYNIN CHLORIDE ER 57 44 39 137
SERTRALINE HCL 56 46 40 25
PROAIR HFA 56 40 40 32
NIASPAN 55 41 42 159
DOXAZOSIN MESYLATE 55 55 42 55
TAMSULOSIN HCL 54 43 44 27
DILTIAZEM ER 53 53 45 130
PANTOPRAZOLE SODIUM 52 48 46 40
TRIAMTERENE-HCTZ 51 51 47 42
OXYCODONE HCL 50 42 S2 48 24
LANTUS SOLOSTAR 50 29 48 94
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 30, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.